Volume 7.48 | Dec 10 - Cord Blood News

Cord Blood News 7.48 December 10, 2015

TOP STORY

Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft
Researchers evaluated the feasibility and safety of StemRegenin-1 (SR-1), an aryl hydrocarbon receptor antagonist that expands CD34⁺ cells, by placing one of the two units in expansion culture. SR-1 produced a 330-fold increase in CD34⁺ cells and led to engraftment in 17/17 patients at a median of 15 days for neutrophils and 49 days for platelets, significantly faster than in patients treated with unmanipulated umbilical cord blood. [Cell Stem Cell] Abstract | Graphical Abstract

Only One of These Antibodies Will Work for Your Cell Analysis. We Provide Streamlined Solutions that are Reliable and Save You Time

PUBLICATIONS (Ranked by impact factor of the journal)

Umbilical Cord Mesenchymal Stromal Cell with Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion
Scientists determined the safety and effects on insulin secretion of umbilical cord mesenchymal stromal cells plus autologous bone marrow mononuclear cell stem cell transplantation without immunotherapy in established type 1 diabetes. [Diabetes Care] Abstract

Investigating the Potential of Human Placental Derived Extracellular Matrix Sponges Coupled with Amniotic Membrane-Derived Stem Cells for Osteochondral Tissue Engineering
Scientists fabricated human placental derived extracellular matrix sponges (PEMS) for repair of osteochondral tissue through a decellularization process. In vitro, PEMS provided a non-cytotoxic and bioactive cues rich environment for the human amniotic membrane derived stem cells to proliferate and differentiate into chondrogenic and osteogenic lineage under induction. [J Mater Chem B] Abstract

Placenta Mesenchymal Stem Cell Derived Exosomes Confer Plasticity on Fibroblasts
The authors isolated human placenta mesenchymal stem cell-derived exosomes and examined their function in vitro. [J Cell Biochem] Abstract

Mast Cells Release Chemokine CCL2 in Response to Parkinsonian Toxin 1-Methyl-4-Phenyl-Pyridinium (MPP⁺)
Investigators analyzed if MPP⁺ activates mouse and human mast cells to release chemokine (C-C motif) ligand 2 (CCL2). Mouse bone marrow-derived mast cells and human umbilical cord blood-derived cultured mast cells were incubated with MPP⁺ for 24 hours and CCL2 levels were measured in the supernatant media by ELISA. [Neurochem Res] Abstract

Inverse Association between Maternal 25OHD Level and Cord GLP-1/GIP Concentrations
Scientists explored whether maternal 25-hydroxyvitamin D levels in normal pregnancy have association with diabetes-related hormone levels and glycated albumin. A prospective cohort study was performed to collect serum samples from 612 pairs of pregnant women and cord blood of their offspring. [Pediatr Res] Abstract

Isolation and Morphological Characterization of Ovine Amniotic Fluid Mesenchymal Stem Cells
Researchers obtained mesenchymal stem cells from ovine amniotic fluid and determined the expansion capacity, surface and intracellular marker expression, karyotype, and multilineage differentiation ability of these ovine amniotic fluid mesenchymal stem cells. [Exp Anim] Abstract

SmartDish™ with STEMgrid™-6 for Accurate Counting of Hematopoietic CFU Assays

REVIEWS

Methods of Ex Vivo Expansion of Human Cord Blood Cells: Challenges, Successes and Clinical Implications
The authors review the current landscape of cord blood engineering aimed at improving engraftment. This includes approaches of unrelated cord blood-hematopoietic stem and progenitor cells (UCB-HSPCS) expansion and methods aimed at improving UCB-HSCPs homing. [Expert Rev Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

SCIENCE NEWS

Multiple Myeloma Patient Study Shows Promise for Natural Killer Cells
A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient’s own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments. [Press release from MD Anderson Cancer Center discussing research presented at the 57^th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells. Watch the video.

INDUSTRY NEWS

Gamida Cell Reports Positive Top Line Results of International, Multi-Center, Phase I/II Study of NiCord^® for Blood Cancers, Demonstrating Rapid and Durable Hematopoietic Recovery
Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced positive top line results from the Phase I/II study of NiCord, in development as an experimental treatment for patients with blood cancers. [Gamida Cell (Business Wire)] Press Release

Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA™ (Bendamustine Hydrochloride) Injection
Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved BENDEKA™ injection. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. [Teva Pharmaceutical Industries Ltd.] Press Release

NYBC Scientists Awarded Patents for Discoveries to Protect Our Blood Supply and Advance Vaccine Therapies
New York Blood Center announced the award of several new patents, continuing its unique role as an independent, community-based blood center that also operates a successful research institute dedicated to developing products and services that benefit patients worldwide. [New York Blood Center (PR Newswire Association LLC.)] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW The Controlling Cancer Summit 2016
May 17-19, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the cord blood community.

JOB OPPORTUNITIES

NEW Full Member Faculty – Hematopoietic Cell Transplant Program (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Scientist – Lymphocyte Trafficking Mechanisms in Allogeneic Stem-Cell Transplantation (Columbia University Medical Center)

Associate/Full Professor – Stem Cell Biology and Regeneration Medicine (Guangzhou Women and Children’s Medical Center)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Faculty Positions – Regenerative Medicine for Organ Regeneration or Transplantation (The University of Texas Medical School at Houston)

Postdoctoral Fellow – Leukemia Research (City of Hope)

Faculty Member – Hematopoietic Cell Transplant (Fred Hutchinson Cancer Research Center)

Assistant or Associate Professor – Cell and Regenerative Biology (University of Wisconsin, Madison)

Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Cord Blood News: Archives | Events | Contact Us